Anzeige
Mehr »
Login
Freitag, 26.04.2024 Börsentäglich über 12.000 News von 687 internationalen Medien
Geheimtipp: Rasanter Aufstieg, Branchenrevolution und Jahresumsatz von 50 Mio. $
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
35 Leser
Artikel bewerten:
(0)

GranuFlo Lawsuits Continue, as Fresenius Medical Care Announces NaturaLyte Recall in Canada, Bernstein Liebhard LLP Reports

NEW YORK, April 10, 2014 /PRNewswire/ -- As GranuFlo lawsuits (http://www.thegranuflolawsuit.com/)stemming from the 2012 recall of GranuFlo and NaturaLyte dialysis concentrates continue to move forward in the U.S., Bernstein Liebhard LLP notes that Fresenius Medical Care has announced a new NaturaLyte recall in Canada. According to a notification issued by HealthCanada on April 5, 2014, the NaturaLyte recall involves several specific lots of "NaturaLyte Sodium Bicarbonate Liquid Concentrate" that may be contaminated with bacteria. The affected NaturaLyte products were distributed to hospital and home settings in Canada between August 8, 2013 and October 28, 2013. So far, no adverse events have been linked to this issue.

Bernstein Liebhard LLP.

"Our Firm is actively filing GranuFlo lawsuits on behalf of individuals who were harmed by products included in the 2012 GranuFlo and NaturaLyte recall, so this issue is of great interest to us," says Bernstein Liebhard LLP, a nationwide law firm representing individuals harmed by defective medical devices and drugs. Currently, the Firm is offering free and confidential case evaluations to individuals who may have experienced side effects within 72 hours of receiving GranuFlo or NaturaLyte.

2012 GranuFlo Recall

GranuFlo and NaturaLyte are used during hemodialysis to remove toxins from the blood in patients whose kidneys are no longer able to perform this function. The 2012 GranuFlo and NaturaLyte recall was announced after it became apparent that dosage issues were causing patients to suffer serious and catastrophic heart events, including heart attacks, strokes and sudden cardiac death. According to a June 2012 report from The New York Times, many doctors were not aware prior to the GranuFlo recall that in comparison to other dialysis concentrates, GranuFlo and NaturaLyte contained higher amounts of an ingredient the body converts to bicarbonate. Failure to account for this difference can cause patients to develop metabolic alkalosis, a condition related to a dangerous elevation of bicarbonate in the blood that can result in life-threatening heart events.

The U.S. Food & Drug Administration (FDA) ultimately granted Class I status to the 2012 GranuFlo recall, which indicates the products posed a serious risk of injury and death.

According to court documents, more than 650 GranuFlo lawsuits have been filed in a multidistrict litigation underway in U.S. District Court, District of Massachusetts on behalf of individuals who allegedly suffered injuries related to the 2012 GranuFlo recall. Among other things, these lawsuits claim that Fresenius was aware of problems long before the recall was announced, but failed to notify the public in order to protect sales of GranuFlo and NaturaLyte. Among other things, plaintiffs point out that Fresenius issued an internal memo to its own dialysis clinics in November 2011 to advise doctors practicing at those facilities about the dosage issues associated with GranuFlo and NaturaLyte. The lawsuits question why a similar notification was not issued to dialysis clinics outside the company's network at that time. (In re Fresenius GranuFlo/Naturalyte Dialysate Litigation, MDL No. 2428)

Dialysis patients who may have suffered cardiovascular side effects within 72 hours of receiving GranuFlo or NaturaLyte may be eligible to file a lawsuit against Fresenius Medical Care. Learn more about the GranuFlo recall by visiting Bernstein Liebhard LLP's website, or by speaking with one of the Firm's lawyers directly. To arrange for a free case review, please call 800-511-5092.

About Bernstein Liebhard LLP

Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993, including those who have been harmed by dangerous drugs, defective medical devices and consumer products. The firm has been named by The National Law Journal to the Plaintiffs' Hot List, recognizing the top plaintiffs firms in the country, for the past 12 consecutive years. Bernstein Liebhard LLP is the only firm in the country to be named to this prestigious list every year since the list was first published in 2003.

Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
800-511-5092

ATTORNEY ADVERTISING. © 2014 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Contact Information:
Felecia L. Stern, Esq.
Bernstein Liebhard LLP
info(at)consumerinjurylawyers(dot)com
http://www.thegranuflolawsuit.com/
https://plus.google.com/115936073311125306742?rel=author

Logo- http://photos.prnewswire.com/prnh/20120202/MM47134LOGO

SOURCE Bernstein Liebhard LLP

Großer Insider-Report 2024 von Dr. Dennis Riedl
Wenn Insider handeln, sollten Sie aufmerksam werden. In diesem kostenlosen Report erfahren Sie, welche Aktien Sie im Moment im Blick behalten und von welchen Sie lieber die Finger lassen sollten.
Hier klicken
© 2014 PR Newswire
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.